Large-scale manufacturing and characterization of CMV-CD19CAR T cells
Background Adoptive transfer of CD19-specific chimeric antigen receptor (CD19CAR) T cells can induce dramatic disease regression in patients with B cell malignancies. CD19CAR T cell therapy may be limited by insufficient engraftment and persistence, resulting in tumor relapse. We previously demonstr...
Saved in:
Main Authors: | Stephen J Forman, Xiuli Wang, Ryan Urak, Miriam Walter, Min Guan, Tianxu Han, Vibhuti Vyas, Sheng-Hsuan Chien, Brenna Gittins, Mary C Clark, Sally Mokhtari, Angelo Cardoso, Don J Diamond, John Zaia, Ryotaro Nakamura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/1/e003461.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01) -
COVID-19 reactivating CMV or CMV complicating COVID-19: A need to conquer
by: Areena Hoda Siddiqui, et al.
Published: (2023-07-01) -
CMV Pancreatitis in an Immunocompromised Patient
by: Jaffer Ahmad, et al.
Published: (2021-01-01) -
Repeated CMV Infection in a Heart Transplantation Patient
by: Josep Melero-Ferrer, et al.
Published: (2012-01-01) -
Incidence of ophthalmic manifestations in congenital cytomegalovirus (CMV)
by: Jennifer L. Rossen, et al.
Published: (2025-01-01)